South Korea Considers Restarting Market-based Actual Transaction Price System
This article was originally published in PharmAsia News
Faced with opposition from pharma companies jittery over the potential for more price cuts, the Ministry of Health and Welfare is considering a market-based actual transaction pricing system, which awards institutions for buying cheaper drugs.
You may also be interested in...
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.